CY1124828T1 - Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης - Google Patents

Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης

Info

Publication number
CY1124828T1
CY1124828T1 CY20211101106T CY211101106T CY1124828T1 CY 1124828 T1 CY1124828 T1 CY 1124828T1 CY 20211101106 T CY20211101106 T CY 20211101106T CY 211101106 T CY211101106 T CY 211101106T CY 1124828 T1 CY1124828 T1 CY 1124828T1
Authority
CY
Cyprus
Prior art keywords
disease
compounds
allosteric modulators
acetylcholine receptors
nicotine acetylcholine
Prior art date
Application number
CY20211101106T
Other languages
English (en)
Inventor
Brendan M. Crowley
Brian T. Campbell
Joseph L. Duffy
Thomas J. Greshock
Andrew John Harvey
Belinda C. Huff
Kenneth J. Leavitt
Vanessa L. Rada
John M. Sanders
William D. Shipe
Linda M. Suen
Ian M. Bell
Deodial G. GUIADEEN
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1124828T1 publication Critical patent/CY1124828T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Control Of El Displays (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα αποκάλυψη σχετίζεται με ενώσεις του χημικού τύπου (Ι) που είναι χρήσιμες ως διαμορφωτές του α7 nAChR, συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις, και τη χρήση τέτοιων ενώσεων για πρόληψη, αγωγή, ή βελτίωση πάθησης, ειδικότερα διαταραχών του κεντρικού νευρικού συστήματος όπως είναι οι γνωσιακές εξασθενίσεις σε νόσο του Αλτσχάιμερ, νόσο του Πάρκινσον, και σχιζοφρένεια, ως επίσης και για επαγόμενη από L-DOPA δυσκινησία και φλεγμονή.
CY20211101106T 2016-03-22 2021-12-16 Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης CY1124828T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311888P 2016-03-22 2016-03-22
US201662369778P 2016-08-02 2016-08-02
PCT/US2017/023127 WO2017165256A1 (en) 2016-03-22 2017-03-20 Allosteric modulators of nicotinic acetylcholine receptors

Publications (1)

Publication Number Publication Date
CY1124828T1 true CY1124828T1 (el) 2022-11-25

Family

ID=58455680

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211101106T CY1124828T1 (el) 2016-03-22 2021-12-16 Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης

Country Status (40)

Country Link
US (3) US20190337910A1 (el)
EP (2) EP3433234B1 (el)
JP (1) JP6526352B2 (el)
KR (1) KR102203552B1 (el)
CN (1) CN109153649B (el)
AR (1) AR107928A1 (el)
AU (1) AU2017237930B2 (el)
CA (1) CA3018185C (el)
CL (1) CL2018002697A1 (el)
CO (1) CO2018009889A2 (el)
CR (1) CR20180452A (el)
CY (1) CY1124828T1 (el)
DK (1) DK3433234T3 (el)
DO (1) DOP2018000204A (el)
EC (1) ECSP18078877A (el)
ES (1) ES2901197T3 (el)
GE (1) GEP20207149B (el)
HR (1) HRP20211960T1 (el)
HU (1) HUE057460T2 (el)
IL (1) IL261807A (el)
JO (1) JOP20170067B1 (el)
LT (1) LT3433234T (el)
MA (1) MA43756B1 (el)
MD (1) MD3433234T2 (el)
MX (1) MX2018011453A (el)
MY (1) MY195948A (el)
NZ (1) NZ747408A (el)
PE (1) PE20181851A1 (el)
PH (1) PH12018502028A1 (el)
PL (1) PL3433234T3 (el)
PT (1) PT3433234T (el)
RS (1) RS62704B1 (el)
SG (1) SG11201808220VA (el)
SI (1) SI3433234T1 (el)
SV (1) SV2018005743A (el)
TN (1) TN2018000322A1 (el)
TW (1) TWI616438B (el)
UA (1) UA120571C2 (el)
WO (1) WO2017165256A1 (el)
ZA (1) ZA201806141B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9781935B2 (en) 2015-04-17 2017-10-10 Dow Agrosciences Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
EP3964495A1 (en) 2016-10-12 2022-03-09 Dow AgroSciences LLC Molecules having pesticidal utility, and compositions, and processes, related thereto
EP3534888B1 (en) * 2016-11-01 2022-04-06 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
WO2019000238A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019060210A1 (en) 2017-09-19 2019-03-28 Merck Sharp & Dohme Corp. HETEROARYLIC ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
UA126834C2 (uk) * 2018-05-01 2023-02-08 Мерк Шарп Енд Доум Елелсі Спіропіперидинові алостеричні модулятори нікотинових ацетилхолінових рецепторів
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231333B1 (hu) * 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) * 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
TW202408984A (zh) * 2018-11-26 2024-03-01 美商富曼西公司 用於防治無脊椎害蟲的間二醯胺化合物
WO2020223136A1 (en) * 2019-05-02 2020-11-05 Merck Sharp & Dohme Corp. Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
EP4054569A4 (en) * 2019-11-05 2023-10-25 Merck Sharp & Dohme LLC SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
CN111233783B (zh) * 2020-03-13 2021-11-16 温州大学 异噻唑-4-基二硫化物衍生物的合成方法
EP4404934A1 (en) * 2021-09-21 2024-07-31 Merck Sharp & Dohme LLC Allosteric modulators of nicotinic acetylcholine receptors
JP2024539008A (ja) * 2021-10-12 2024-10-28 ブラウン ユニバーシティ 多形膠芽腫処置

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487154A (en) 1967-04-03 1969-12-30 Smithkline Corp Method of lowering blood pressure
US3522302A (en) 1967-05-16 1970-07-28 Smithkline Corp P-(2-aminocycloalkyl)benzenesulfonamides
FR2508033A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Aryl-1 aminomethyl-2 cyclopropanes carboxylates (z), leur preparation et leur application en tant que medicaments utiles dans le traitement d'algies diverses
US5286736A (en) 1990-11-22 1994-02-15 Dr. Karl Thomae Gmbh Pyridyl compounds and pharmaceutical compositions containing these compounds
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
FR2751645B1 (fr) 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
TW530058B (en) 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
ATE232866T1 (de) 1998-02-17 2003-03-15 Astrazeneca Uk Ltd Neue triazolo(4,5d) pyrimidinverbindungen
SE9802574D0 (sv) 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2001227122A1 (en) 2000-01-29 2001-08-07 Lg Chem Investment Ltd. Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
FR2810664B1 (fr) * 2000-06-27 2004-12-24 Adir Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2004531506A (ja) 2001-03-29 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的なセロトニン再取り込みインヒビターとしてのシクロプロピルインドール誘導体
WO2003082190A2 (en) 2002-03-26 2003-10-09 Merck & Co., Inc. Spirocyclic amides as cannabinoid receptor modulators
CA2509086C (en) 2003-01-06 2012-08-21 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
EP1833804A1 (en) * 2004-12-28 2007-09-19 AstraZeneca AB Aryl sulphonamide modulators
US8470985B2 (en) * 2005-08-24 2013-06-25 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
CN102058571B (zh) 2005-09-09 2012-09-19 有限会社肯菲思 4-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸在制备用于预防及/或治疗肠疾病的药物中的应用
AU2008307195B2 (en) * 2007-10-04 2012-11-22 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
BRPI0821197A2 (pt) 2007-12-19 2015-06-16 Amgen Inc Composto, composição farmacêutica, uso de um composto, processo, e, intermediário.
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2323971B1 (en) 2008-08-12 2012-05-09 F. Hoffmann-La Roche AG Salicylamide derivatives as nicotinic alpha 7 modulators
SG172289A1 (en) 2008-12-19 2011-07-28 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EP2337781B1 (en) 2009-06-11 2014-07-23 AbbVie Bahamas Ltd. Anti-viral compounds to treat hcv infection
WO2010144959A1 (en) 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues of anti-fibrotic agents
EP2464228B1 (en) 2009-08-13 2017-12-06 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012012410A2 (en) 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
JP2013540767A (ja) 2010-10-07 2013-11-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 免疫不全ウイルス転写を調節するための組成物および方法
EP2651885A1 (en) 2010-12-16 2013-10-23 Abbvie Inc. Anti-viral compounds
KR101925971B1 (ko) 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
EP2670731B1 (en) 2011-02-02 2016-05-25 Bionomics Limited Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof.
CA2826792A1 (en) * 2011-02-23 2012-08-30 Lupin Limited Heteroaryl derivatives as alpha7 nachr modulators
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2013005153A1 (en) * 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
US8598213B2 (en) 2011-07-08 2013-12-03 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
UA111746C2 (uk) * 2011-07-08 2016-06-10 Х. Луннбек А/С Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну
US8912202B2 (en) 2011-08-08 2014-12-16 Merck Patent Gmbh N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
WO2014006117A1 (en) 2012-07-06 2014-01-09 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
MX2015001512A (es) * 2012-08-01 2015-08-20 Merck Sharp & Dohme Moduladores del receptor nicotínico alfa 7 de acetilcolina y sus usos-i.
EP2928860A1 (en) 2012-12-10 2015-10-14 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
EP2968440B1 (en) 2013-03-15 2019-06-05 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US9593096B2 (en) 2013-04-24 2017-03-14 Merck Sharp & Dohme Corp. α7 nicotinic acetylcholine receptor modulators and uses thereof-III
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
CA2935064C (en) 2013-12-27 2023-06-27 Zymeworks Inc. Var2csa-drug conjugates
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
CA2949785A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse For Medicinsk Forskning Mth1 inhibitors for treatment of cancer
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
WO2015191799A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof

Also Published As

Publication number Publication date
JOP20170067B1 (ar) 2021-08-17
CA3018185C (en) 2020-09-15
ECSP18078877A (es) 2019-02-28
AU2017237930A1 (en) 2018-10-11
EP3433234A1 (en) 2019-01-30
HUE057460T2 (hu) 2022-05-28
DK3433234T3 (da) 2022-01-03
TWI616438B (zh) 2018-03-01
CO2018009889A2 (es) 2018-10-22
US9926285B2 (en) 2018-03-27
MA43756A (fr) 2021-05-19
CN109153649B (zh) 2022-04-19
US20180030007A1 (en) 2018-02-01
IL261807A (en) 2018-10-31
ES2901197T3 (es) 2022-03-21
MA43756B1 (fr) 2021-11-30
GEP20207149B (en) 2020-09-10
LT3433234T (lt) 2021-12-10
JP6526352B2 (ja) 2019-06-05
PT3433234T (pt) 2021-12-22
RS62704B1 (sr) 2022-01-31
EP3433234B1 (en) 2021-10-27
CL2018002697A1 (es) 2018-12-28
UA120571C2 (uk) 2019-12-26
PE20181851A1 (es) 2018-12-03
CR20180452A (es) 2019-02-06
US9840481B2 (en) 2017-12-12
SI3433234T1 (sl) 2022-01-31
TN2018000322A1 (en) 2020-01-16
KR102203552B1 (ko) 2021-01-18
EP3978479A1 (en) 2022-04-06
MD3433234T2 (ro) 2022-02-28
JP2019512508A (ja) 2019-05-16
HRP20211960T1 (hr) 2022-03-18
US20170275260A1 (en) 2017-09-28
AU2017237930B2 (en) 2019-02-07
TW201733989A (zh) 2017-10-01
DOP2018000204A (es) 2019-07-15
PH12018502028A1 (en) 2019-07-15
MY195948A (en) 2023-02-27
KR20180127644A (ko) 2018-11-29
ZA201806141B (en) 2019-08-28
SV2018005743A (es) 2019-01-18
CA3018185A1 (en) 2017-09-28
AR107928A1 (es) 2018-06-28
NZ747408A (en) 2024-07-05
US20190337910A1 (en) 2019-11-07
WO2017165256A1 (en) 2017-09-28
CN109153649A (zh) 2019-01-04
SG11201808220VA (en) 2018-10-30
PL3433234T3 (pl) 2022-01-24
MX2018011453A (es) 2019-01-10
BR112018069456A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
CY1124828T1 (el) Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης
CY1124113T1 (el) Συνθεσεις και μεθοδοι για την θεραπευτικη αντιμετωπιση διαταραχων κνς
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
ECSP16025201A (es) Profármacos de amidas de piridona útiles como moduladores de canales de sodio
CY1120846T1 (el) 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA201700042A1 (ru) Соединения имидазопиридазина
CY1121898T1 (el) Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA202090414A1 (ru) Соединения и их применение
CL2020002820A1 (es) Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina .
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
EA201790315A1 (ru) Модуляторы x-рецепторов печени
PH12019500198A1 (en) Compounds and compositions and uses thereof
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
CY1123185T1 (el) Παραγωγα ινδολιου
CL2017002651A1 (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний